Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Net Cash Flow (2016 - 2025)

Immucell (ICCC) has disclosed Net Cash Flow for 16 consecutive years, with -$2.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Cash Flow fell 185.02% year-over-year to -$2.1 million, compared with a TTM value of $77565.0 through Sep 2025, down 95.74%, and an annual FY2024 reading of $2.8 million, up 157.75% over the prior year.
  • Net Cash Flow was -$2.1 million for Q3 2025 at Immucell, down from $1.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $3.9 million in Q2 2021 and bottomed at -$3.0 million in Q4 2022.
  • Average Net Cash Flow over 5 years is -$161249.4, with a median of -$143287.0 recorded in 2021.
  • The sharpest move saw Net Cash Flow crashed 981.81% in 2022, then surged 4672.9% in 2025.
  • Year by year, Net Cash Flow stood at -$310291.0 in 2021, then crashed by 878.5% to -$3.0 million in 2022, then soared by 66.71% to -$1.0 million in 2023, then soared by 95.01% to -$50401.0 in 2024, then tumbled by 4090.98% to -$2.1 million in 2025.
  • Business Quant data shows Net Cash Flow for ICCC at -$2.1 million in Q3 2025, $1.4 million in Q2 2025, and $841139.0 in Q1 2025.